Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Código da empresaMRKR
Nome da EmpresaMarker Therapeutics Inc
Data de listagemNov 08, 2016
Fundado em2018
CEODr. Juan F. Vera, M.D.
Número de funcionários5
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 08
Endereço2450 Holcombe Blvd
CidadeHOUSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal77021
Telefone17134006400
Sitehttps://markertherapeutics.com/
Código da empresaMRKR
Data de listagemNov 08, 2016
Fundado em2018
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados